Sobi in €387m orphan drug deal with Novimmune
The exclusive licence agreement will give Sobi the rights to emapalumab, an anti-interferon-gamma monoclonal antibody, which currently being reviewed...
Roche presents biomarker test to identify NSCLC responders to Tecentriq
In Nature Medicine, the researchers reported that a mutation frequency of 16 mutations per megabase DNA or above that threshold predicted best...
New antibiotics on the block
For developers of antimicrobial resistance breakers, the meeting organized by the European Society of Clinical Microbiology and Infectious Diseases...
Roche providing improved anti-Her2 bispecific antibody
Dose escalation trails dating back to 2006 have provided severe toxicity for Trion Pharma's/Fresenius' bispecific anti-HER2 x anti-CD3 antibody...
Big Data: Tracking cancer risk genes
Cancer may be due to lifestyle or pure chance, but a major cause is genetic predisposition. Three researchers at the Barcelona Centre for Genomic...
EIB incentivises bioeconomy investments
The €500m (US ($580.80m) transaction represents the first EIB funding intended to directly support sustainable finance. “We have selected the water...
TxCell snapped up by Sangamo
The merger will combine TxCell’s expertise in the field of regulatory T cell (Treg) development for immunological diseases with Sangamo’s ex vivo...